-
1
-
-
27844454796
-
-
For a recent review, see for example: Reese, C. B. Org. Biomol. Chem. 2005, 3, 3851.
-
(2005)
Org. Biomol. Chem.
, vol.3
, pp. 3851
-
-
Reese, C.B.1
-
2
-
-
0141538236
-
-
For a recent review, see for example: Natarajan, V.; Jeong, K. S.; Byeang, K. Curr. Med. Chem. 2003, 10, 1973.
-
(2003)
Curr. Med. Chem.
, vol.10
, pp. 1973
-
-
Natarajan, V.1
Jeong, K.S.2
Byeang, K.3
-
4
-
-
0037038995
-
-
(a) Reese, C. B.; Yan, H. J. Chem. Soc., Perkin Trans. 1 2002, 23, 2619.
-
(2002)
J. Chem. Soc., Perkin Trans. 1
, vol.23
, pp. 2619
-
-
Reese, C.B.1
Yan, H.2
-
6
-
-
0031887059
-
-
Reese, C. B.; Song, Q.; Rao, M. V.; Beckett, I. Nucleosides Nucleotides 1998, 17, 451.
-
(1998)
Nucleosides Nucleotides
, vol.17
, pp. 451
-
-
Reese, C.B.1
Song, Q.2
Rao, M.V.3
Beckett, I.4
-
7
-
-
0034843993
-
-
(a) Kozai, S.; Maruyama, T.; Kimura, T.; Yamamoto, I. Chem. Pharm. Bull. 2001, 49, 1185.
-
(2001)
Chem. Pharm. Bull.
, vol.49
, pp. 1185
-
-
Kozai, S.1
Maruyama, T.2
Kimura, T.3
Yamamoto, I.4
-
8
-
-
17744413616
-
-
(b) Robles, R.; Rodrìguez, C.; Izquierdo, I.; Plaza, M. T.; Mota, A.; Cienfuegos, L. A. Tetrahedron: Asymmetry 2000, 11, 3069.
-
(2000)
Tetrahedron: Asymmetry
, vol.11
, pp. 3069
-
-
Robles, R.1
Rodrìguez, C.2
Izquierdo, I.3
Plaza, M.T.4
Mota, A.5
Cienfuegos, L.A.6
-
10
-
-
0038697333
-
-
(d) Dobson, N.; McDowell, D. G.; French, D. J.; Brown, L. J.; Mellor, J. M.; Brown, T. Chem. Commun. 2003, 1234.
-
(2003)
Chem. Commun.
, pp. 1234
-
-
Dobson, N.1
McDowell, D.G.2
French, D.J.3
Brown, L.J.4
Mellor, J.M.5
Brown, T.6
-
11
-
-
25444497717
-
-
D'Onofrio, J.; de Champdoré, M.; De Napoli, L.; Montesarchio, D.; Di Fabio, G. Bioconjugate Chem. 2005, 16, 1299.
-
(2005)
Bioconjugate Chem.
, vol.16
, pp. 1299
-
-
D'Onofrio, J.1
De Champdoré, M.2
De Napoli, L.3
Montesarchio, D.4
Di Fabio, G.5
-
12
-
-
15644384134
-
-
Hotoda, H.; Koizumi, M.; Koga, R.; Kaneko, M.; Momota, K.; Ohmine, T.; Furukawa, H.; Agatluma, T.; Nishigaki, T.; Sone, J.; Tsutsumi, S.; Kosaka, T.; Abe, K.; Kimura, S.; Shimada, K. J. Med. Chem. 1998, 41, 3655.
-
(1998)
J. Med. Chem.
, vol.41
, pp. 3655
-
-
Hotoda, H.1
Koizumi, M.2
Koga, R.3
Kaneko, M.4
Momota, K.5
Ohmine, T.6
Furukawa, H.7
Agatluma, T.8
Nishigaki, T.9
Sone, J.10
Tsutsumi, S.11
Kosaka, T.12
Abe, K.13
Kimura, S.14
Shimada, K.15
-
13
-
-
0028340635
-
-
Hotoda, H.; Momota, K.; Furukawa, H.; Nakamura, T.; Kaneko, M. Nucleosides Nucleotides 1994, 13, 1375.
-
(1994)
Nucleosides Nucleotides
, vol.13
, pp. 1375
-
-
Hotoda, H.1
Momota, K.2
Furukawa, H.3
Nakamura, T.4
Kaneko, M.5
-
14
-
-
1542470317
-
-
Jaksa, S.; Kralj, B.; Pannecouque, C.; Balzarini, J.; De Clercq, E.; Kobe, J. Nucleosides, Nucleotides Nucleic Acids 2004, 23, 77.
-
(2004)
Nucleosides, Nucleotides Nucleic Acids
, vol.23
, pp. 77
-
-
Jaksa, S.1
Kralj, B.2
Pannecouque, C.3
Balzarini, J.4
De Clercq, E.5
Kobe, J.6
-
15
-
-
0029799743
-
-
Schelhaas, M.; Waldmann, H. Angew. Chem., Int. Ed. Engl. 1996, 35, 2056.
-
(1996)
Angew. Chem., Int. Ed. Engl.
, vol.35
, pp. 2056
-
-
Schelhaas, M.1
Waldmann, H.2
-
18
-
-
33645789539
-
-
note
-
+].
-
-
-
-
19
-
-
33645765260
-
-
note
-
3-pyridine (1:0.05)], affording 745 mg (0.98 mmol, 65%) of pure 2.
-
-
-
-
20
-
-
0035930717
-
-
(a) deChampdoré, M.; De Napoli, L.; Di Fabio, G.; Messere, A.; Montesarchio, D.; Piccialli, G. Chem. Commun. 2001, 2598.
-
(2001)
Chem. Commun.
, pp. 2598
-
-
Dechampdoré, M.1
De Napoli, L.2
Di Fabio, G.3
Messere, A.4
Montesarchio, D.5
Piccialli, G.6
-
21
-
-
4544244942
-
-
(b) De Napoli, L.; Di Fabio, G.; D'Onofrio, J.; Montesarchio, D. Synlett 2004, 1975.
-
(2004)
Synlett
, vol.1975
-
-
De Napoli, L.1
Di Fabio, G.2
D'Onofrio, J.3
Montesarchio, D.4
-
23
-
-
33645774637
-
-
note
-
+].
-
-
-
-
24
-
-
33645779268
-
-
note
-
3-pyridine (1:0.05)], affording 980 mg (1.23 mmol, 90%) of pure 3.
-
-
-
-
25
-
-
33645773636
-
-
note
-
+].
-
-
-
-
26
-
-
33645791245
-
-
note
-
3 at 55 °C after an overnight treatment was only partial, requiring longer reaction times to go to completion (ca. 72 h). On the other hand, a 0.1 M NaOH solution ensured complete thymine deprotection after an overnight treatment at 50 °C, i.e. conditions usually adopted also for oligonucleotide deprotection and detachment from the solid support.
-
-
-
-
27
-
-
33645756316
-
-
note
-
-.
-
-
-
|